BLAINTRAVENOUSINJECTABLE
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POHERDY (pertuzumab-dpzb) is a biosimilar monoclonal antibody targeting HER2, approved as an intravenous injectable therapy. As a pertuzumab biosimilar, it replicates the mechanism of action of the reference biologic in HER2-positive malignancies and other HER2-driven conditions. This product represents Shanghai Henlius Biotech's entry into the competitive oncology biosimilar market.
Launch
Early-stage launch with moderate competitive pressure (30/100) signals resource allocation toward market penetration and payer engagement teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POHERDY launch roles will focus on competitive positioning against established pertuzumab and other HER2-targeted therapies, with emphasis on payer negotiations and biosimilar-specific educational content. Career growth is tied to successful market penetration and volume capture in a moderate-competition environment.
Brand ManagerMarket Access Manager
Worked on POHERDY at Shanghai Henlius Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.